20th Jan 2022 10:41
(Alliance News) - Beximco Pharmaceuticals Ltd announced on Thursday that it has been granted a licence to produce Covid-19 treatment molnupiravir.
The Dhaka, Bangladesh-based pharmaceutical company said it is now included in the United Nations-backed Medicines Patent Pool. As a result, it has been granted a licence to produce molnupirvair.
Molnupiravir is an oral antiviral to treat symptomatic Covid-19. It received conditional marketing authorisation in the UK in November and emergency use authorisation in the US in December.
The treatment was originally developed by New Jersey, US-based pharmaceutical company Merck & Co Inc in partnership with Florida-based biotechnology company Ridgeback Biotherapeutics LP.
Beximco will manufacture molnupiravir in Bangladesh and said it expects to start domestic distribution and export from the end of 2022.
The company will continue to sell its own generic version of molnupiravir, known as Emorivir, in the meantime.
Shares in Beximco were up 5.5% at 116.00 pence on Thursday morning in London.
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Beximco Pharma